Program
filgotinib
Also written as “Filgotinib”, “GLPG0634” and “GLPG0634 50 mg”.
Its studies are mostly in Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Arthritis, Psoriatic · Arthritis, Juvenile, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lakefront Biotherapeutics NV | 230 open or running | phase 3since Sep 22, 2016 | Aug 10, 2010 | none ahead |
| Gilead Sciences | 160 open or running | phase 3since Aug 17, 2016 | Aug 17, 2016 | none ahead |
| Alfasigma | 74 open or running | phase 3since Sep 22, 2016 | Sep 22, 2016 | Jun 2027phase 3 · NCT07554495 |
Also a collaborator on its studies: Ono Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 29 studies since Aug 10, 2010.
- Jun 30, 2017Phase 2 study in Noninfectious UveitisGilead Sciences · NCT03207815 · 74 enrolled · United States, Australia, Canada and more
- Sep 14, 2017Phase 2 study in Lupus Membranous NephropathyGilead Sciences · NCT03285711 · 9 enrolled · United States
- Oct 20, 2017Phase 2 study in Arthritis, PsoriaticLakefront Biotherapeutics NV · NCT03320876 · 122 enrolled · Belgium, Bulgaria, Czechia and more
- Jan 25, 2018Phase 1 study in Arthritis, RheumatoidGilead Sciences · NCT03417778 · 20 enrolled · United States, Germany, New Zealand
- Apr 19, 2019Phase 2 study in Arthritis, RheumatoidLakefront Biotherapeutics NV · NCT03926195 · 109 enrolled · Bulgaria, Czechia, Estonia and more
- Oct 2, 20192 phase 3 studies in Arthritis, PsoriaticGilead Sciences · NCT04115839, NCT04115748
- Jul 20, 20202 phase 3 studies in Spondylitis, AnkylosingGilead Sciences · NCT04483700, NCT04483687
- Oct 23, 2020Phase 1 study in Arthritis, RheumatoidGilead Sciences · NCT04608344 · 27 enrolled · United States
- Jul 26, 2022Phase 3 study in Colitis, UlcerativeLakefront Biotherapeutics NV · NCT05479058 · 22 enrolled · United States, Belgium, Czechia and more
- Mar 14, 2023Phase 3 study in Axial SpondyloarthritisAlfasigma · NCT05785611 · 495 enrolled · Belgium, Bulgaria, Czechia and more
- Sep 11, 2023Phase 1 study in BioavailabilityLakefront Biotherapeutics NV · NCT06043739 · 12 enrolled · Canada
- Jan 4, 2024Phase 1 study in Arthritis, JuvenileAlfasigma · NCT06222034 · 9 enrolled · France, Germany, Poland and more
- Mar 4, 2025Phase 3 study in Colitis, UlcerativeAlfasigma · NCT06865417 · 80 planned · Belgium, Croatia, France and more
- Apr 15, 20262 phase 3 studies in Arthritis, JuvenileAlfasigma · NCT07554495, NCT07553182
Ahead
- Jun 2027Primary completion: phase 3 study in Arthritis, JuvenileAlfasigma · NCT07554495
- Dec 2027Primary completion: phase 3 study in Arthritis, JuvenileAlfasigma · NCT07553182
- Jun 2028Primary completion: phase 3 study in Colitis, UlcerativeAlfasigma · NCT06865417
TargetBeta
“An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
All 46 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07553182Arthritis, Juvenile · France, Germany, United Kingdom | 3 | Recruiting | Alfasigma | Dec 2027 | 80 |
| NCT07554495Arthritis, Juvenile · Belgium, Czechia, France and more | 3 | Recruiting | Alfasigma | Jun 2027 | 65 |
| NCT06865417Colitis, Ulcerative · Belgium, Croatia, France and more | 3 | Recruiting | Alfasigma | Jun 2028 | 80 |
| NCT06222034Arthritis, Juvenile · France, Germany, Poland and more | 1 | Terminated | Alfasigma | Jun 17, 2026 | 9 |
| NCT06043739Bioavailability · Canada | 1 | Completed | Lakefront Biotherapeutics NV | Oct 27, 2023 | 12 |
| NCT05785611Axial Spondyloarthritis · Belgium, Bulgaria, Czechia and more | 3 | Active, not recruiting | Alfasigma | Sep 4, 2024 | 495 |
| NCT05479058Colitis, Ulcerative · United States, Belgium, Czechia and more | 3 | Terminated | Lakefront Biotherapeutics NV | Oct 9, 2023 | 22 |
| NCT04608344Arthritis, Rheumatoid · United States | 1 | Completed | Gilead Sciences | Jan 13, 2021 | 27 |
| NCT04483700Spondylitis, Ankylosing | 3 | Withdrawn | Gilead Sciences | Oct 2022 | 0 |
| NCT04483687Spondylitis, Ankylosing | 3 | Withdrawn | Gilead Sciences | Jan 2023 | 0 |
| NCT04115839Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Terminated | Gilead Sciences | Jan 4, 2021 | 106 |
| NCT04115748Arthritis, Psoriatic · United States, Australia, Bulgaria and more | 3 | Terminated | Gilead Sciences | Jan 19, 2021 | 67 |
| NCT03926195Arthritis, Rheumatoid · Bulgaria, Czechia, Estonia and more | 2 | Completed | Lakefront Biotherapeutics NV | Aug 14, 2020 | 109 |
| NCT03417778Arthritis, Rheumatoid · United States, Germany, New Zealand | 1 | Completed | Gilead Sciences | Aug 9, 2018 | 20 |
| NCT03320876Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more | 2 | Terminated | Lakefront Biotherapeutics NV | Jun 30, 2021 | 122 |
| NCT03285711Lupus Membranous Nephropathy · United States | 2 | Completed | Gilead Sciences | May 3, 2019 | 9 |
| NCT03207815Noninfectious Uveitis · United States, Australia, Canada and more | 2 | Terminated | Gilead Sciences | Dec 29, 2020 | 74 |
| NCT03201445Inflammatory Bowel Diseases · United States, Australia, Austria and more | 2 | Terminated | Lakefront Biotherapeutics NV | Nov 20, 2020 | 139 |
| NCT03134222Lupus Erythematosus, Cutaneous · United States, Canada | 2 | Completed | Gilead Sciences | Mar 13, 2019 | 47 |
| NCT03100942Sjogren's Syndrome · United States, Poland, Spain and more | 2 | Completed | Gilead Sciences | Jan 10, 2019 | 152 |
| NCT03117270Spondylitis, Ankylosing · Belgium, Bulgaria, Czechia and more | 2 | Completed | Lakefront Biotherapeutics NV | Jul 2, 2018 | 116 |
| NCT03101670Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more | 2 | Completed | Lakefront Biotherapeutics NV | Mar 12, 2018 | 131 |
| NCT03077412Fistulizing Crohn's Disease · United States, Austria, Belgium and more | 2 | Completed | Gilead Sciences | Jan 20, 2021 | 57 |
| NCT03046056Small Bowel Crohn's Disease · United States, Austria, Belgium and more | 2 | Completed | Gilead Sciences | Jul 20, 2020 | 78 |
| NCT03025308Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Alfasigma | May 16, 2025 | 2,731 |
| NCT02914600Crohn Disease · United States, Argentina, Australia and more | 3 | Terminated | Lakefront Biotherapeutics NV | Aug 1, 2023 | 1,188 |
| NCT02914561Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | Lakefront Biotherapeutics NV | Nov 11, 2022 | 1,372 |
| NCT02914535Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Alfasigma | Sep 8, 2026 | 1,173 |
| NCT02914522Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Gilead Sciences | Mar 31, 2020 | 1,351 |
| NCT02889796Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Gilead Sciences | Jul 4, 2018 | 1,759 |
| NCT02886728Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Gilead Sciences | Oct 5, 2018 | 1,252 |
| NCT02873936Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Gilead Sciences | Mar 20, 2018 | 449 |
| NCT02162355Healthy · United Kingdom | 1 | Completed | Lakefront Biotherapeutics NV | Sep 2014 | 36 |
| NCT02084199Renal Insufficiency · Germany | 1 | Completed | Lakefront Biotherapeutics NV | Jul 2014 | 24 |
| NCT02065700Arthritis, Rheumatoid · United States, Argentina, Australia and more | 2 | Completed | Lakefront Biotherapeutics NV | Jan 19, 2023 | 739 |
| NCT02048618Crohn Disease · Belgium, Czech Republic, France and more | 2 | Completed | Lakefront Biotherapeutics NV | Nov 2015 | 175 |
| NCT01915667Healthy · Belgium | 1 | Completed | Lakefront Biotherapeutics NV | Sep 2013 | 12 |
| NCT01894516Arthritis, Rheumatoid · United States, Argentina, Australia and more | 2 | Completed | Lakefront Biotherapeutics NV | Mar 5, 2015 | 287 |
| NCT01888874Arthritis, Rheumatoid · United States, Argentina, Australia and more | 2 | Completed | Lakefront Biotherapeutics NV | Feb 18, 2015 | 599 |
| NCT01820806Healthy · United Kingdom | 1 | Completed | Lakefront Biotherapeutics NV | Apr 2013 | 6 |
| NCT01798979Healthy · United States | 1 | Completed | Lakefront Biotherapeutics NV | Apr 2013 | 20 |
| NCT01668641Arthritis, Rheumatoid · Hungary, Moldova, Republic of, Russian Federation and more | 2 | Completed | Lakefront Biotherapeutics NV | Sep 2012 | 91 |
| NCT01665924Healthy · Belgium | 1 | Completed | Lakefront Biotherapeutics NV | Sep 2012 | 36 |
| NCT01419990Healthy · Belgium | 1 | Completed | Lakefront Biotherapeutics NV | Oct 2011 | 16 |
| NCT01384422Arthritis, Rheumatoid · Moldova, Republic of | 2 | Completed | Lakefront Biotherapeutics NV | Nov 2011 | 36 |
| NCT01179581Healthy · Belgium | 1 | Completed | Lakefront Biotherapeutics NV | Mar 2011 | 48 |
How it is read
Names in the registry
- “Filgotinib”, 32 entries
- “GLPG0634”, 11 entries
- “filgotinib”, 3 entries
- “GLPG0634 50 mg”, 1 entry
- “GLPG0634 100 mg”, 1 entry
Codes read as this program: GLPG0634.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 12 studies
- Crohn Disease, 5 studies
- Colitis, Ulcerative, 4 studies
- Arthritis, Psoriatic, 4 studies
- Arthritis, Juvenile, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.